Mesenchymal Stem Cells & MSC-Gro Media
Human Mesenchymal Stem Cells (hMSCs)-hMSCs Derived from Umbilical Cord Blood
MSCGro™ Mesenchymal Stem Cell Media-Proven and Potent Culture Growth and Differentiation Media for Mesenchymal Stem Cells (MSCs)
hMPro™ Human Mesenchymal Progenitors (hMPCs)-hESC Derived
Hahn, Sei Kwang (Pohang-si, KR), Kim, Yun Seop (Seoul, KR), Kong, Won Ho (Pohang-si, KR),Kim, Hyemin (Daegu, KR). HYALURONIC ACID DERIVATIVES AND COMPOSITION FOR CELL-SURFACE ENGINEERING USING THE SAME. United States Patent Application 20170067012.
...Stem cells (purchased from Neuromics Co., Ltd.)...
Yun Seop Kim, Won Ho Kong, Hyemin Kim, Sei Kwang Hahn. Targeted Systemic Mesenchymal Stem Cell Delivery Using Hyaluronate - Wheat Germ Agglutinin Conjugate. http://dx.doi.org/10.1016/j.biomaterials.2016.08.027
...Human MSCs (hMSCs) were purchased from Neuromics Co...
Chelluboina B, Klopfenstein JD, Pinson DM, Wang DZ, Veeravalli KK. Stem cell treatment after cerebral ischemia regulates the gene expression of apoptotic molecules. Neurochemical research. 39(8): 1511-21 DOI: 10.1007/s11064-014-1341-z
...Cryo-preserved hUCBSCs obtained from Neuromics/Vitro Biopharma (Golden, CO) were used to establish cultures in MSC-GRO low serum complete MSC medium according to the provided instructions. Cultures were maintained at 37 C in a humidified atmosphere containing 5 % CO2 with a change of culture medium twice a week. When the cell cultures were about 80 % to 90 % confluent, cells were split and subcultured. Cells were detached, washed twice with sterile phosphate buffered saline (PBS), counted and suspended in sterile saline prior to intravenous administration. The cells were intravenously injected (0.25 × 10(6) cells or 1 × 10(6) cells) via the tail vein...
Hsiao, Y.-S., Kuo, C.-W. and Chen, P. (2013), Multifunctional Graphene–PEDOT Microelectrodes for On-Chip Manipulation of Human Mesenchymal Stem Cells. Adv. Funct. Mater., 23: 4649–4656. doi: 10.1002/adfm.201203631.
The hMSCs (Neuromics, Edina, MN) used in experiments were at passage 3-9. Each passage of hMSCs was maintained on the TCPS dishes with a pre-coating of Geltrex reduced growth factor basement membrane matrix (Invitrogen, CIBCO, NY). All hMSCs were maintained in the growth medium, Dulbecco's modified Eagle's medium-low glucose (DMEM-LG) supplemented with mesenchymal cell growth supplement (MSCGM, Lonza) containing L-glutamine, penicillin, and streptomycin, and incubated in an atmosphere containing 5% CO2 at 37 °C. The medium was replenished every 3 to 4 days.
For osteogenic differentiation, the hMSCs were cultured in the osteogenesis induction medium, DMEM-LG supplemented with mesenchymal stem cell osteogenesis kit (Chemicon, Cat. No. SCR028), and incubated on the TCPS dishes (control) and test devices. To study the drug release from the devices, hMSCs were cultured in the osteogenesis induction medium in the absence of DEX. The fresh medium was replaced every 2 to 3 days.